TB-500 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-17. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Wilson predicted in January 1966 that the various boycotts would force Smith to give in "within a matter of weeks rather than months", but the British and UN sanctions had little effect on Rhodesia, largely because South Africa and Portugal went on trading with the breakaway colony, providing it with oil and other commodities. Clandestine "sanction-busting" trade with other nations also continued, initially at a reduced level and the diminished presence of foreign competitors helped domestic industries to slowly mature and expand. Rhodesia thus avoided the economic collapse predicted by Wilson and gradually became more self-sufficient. The Rhodesian government set up a string of front holding companies in Switzerland, Luxembourg and Liechtenstein to help keep trade open with some success; goods that had been imported from Britain were replaced by Japanese, French and West German equivalents. Even many OAU states, while bombarding Rhodesia with vitriol, continued importing Rhodesian food and other products. The United States created a formal exception in its embargo with the Byrd Amendment of 1971, under which the US replaced its import of chrome from the Soviet Union with Rhodesian chrome ore. This breach of the UN sanctions, passed by the US Congress on the back of anti-communist Cold War considerations, was warmly welcomed by several white Southerners in Congress; it aided the Rhodesian economy until 1977, when the new president, Jimmy Carter, successfully pushed Congress to repeal it.
=== Inverted lymph nodes === Some mammal species, such as pigs, rhinoceroses, hippopotamuses, and certain cetaceans, have so-called "inverted" lymph nodes. In these nodes, the afferent lymph carries antigens from the center (where the B-cell follicles are located) toward the periphery. Mature B and T lymphocytes exit the lymph node from its periphery directly into the general bloodstream via efferent venules. These structural differences do not appear to impact the functionality of the lymph nodes.
== Prognosis == Prognosis depends on the individual form of muscular dystrophy. Some dystrophies cause progressive weakness and loss of muscle function, which may result in severe physical disability and a life-threatening deterioration of respiratory muscles or heart. Other dystrophies do not affect life expectancy and only cause relatively mild impairment.
=== Third week (7–13 March) === On 7 March, Pakistani officials stated that they had carried out air strikes along the Pakistan-Afghanistan border, destroying several Afghan Taliban positions. The officials added the airstrikes inflicted heavy casualties on the Taliban forces, forcing them to abandon and flee from those positions. Meanwhile, Taliban officials said that Pakistani forces had bombed the provinces of Paktia, Paktika, Khost, Maidan Wardak, and Kunar, resulting in civilian casualties and damage to homes and shops. Taliban officials did not comment on the casualties suffered by their forces. Taliban officials also urged the United Nations Security Council (UNSC) to take action to stop Pakistan's attacks. They cited recent strikes on several Afghan provinces, civilian casualties, displacement, and the expulsion and harassment of Afghan refugees in Pakistan, and called on the UNSC to help end the situation. Taliban officials in Torkham border crossing area said that Pakistan's attacks have destroyed at least 150 shops, resulting heavy financial losses for Afghan business owners. In Nangarhar province, residents state that the Taliban had forced them to participate in a protest against Pakistan in Jalalabad, in some cases by offering cash payments. Three Policemen were killed and 31 people including five Policemen and 26 civilians were wounded in an IED attack targeting a police patrol in Wana. A drone attack on relatives of police peace committee killed two and wounded seven in Lakki Marwat District while a bomb blast killed two more civilians and wounded ten.
Sources: en.wikipedia.org
"Homo neanderthalensis". The Smithsonian Institution. February 14, 2010. Human Timeline (Interactive) – Smithsonian, National Museum of Natural History (August 2016). "Neanderthal DNA". International Society of Genetic Genealogy. Archived from the original on June 17, 2006.: Includes Neanderthal mtDNA sequences GenBank records for H. s. neanderthalensis maintained by the National Center for Biotechnology Information (NCBI) Alex, Bridget (February 21, 2024). "What's Behind the Evolution of Neanderthal Portraits". SAPIENS. The Climate Chronicles, explores the impact of Pleistocene climate change on Neanderthals and other hominins.
The United States Food and Drug Administration and the European Medicines Agency have approved weight loss medications for adults with either a body-mass index (BMI) of at least 30, or a body-mass index of at least 27 with at least one weight-related comorbidity. This patient population is considered to have sufficiently high baseline health risks to justify the use of anti-obesity medication. The American Academy of Pediatrics had not previously supported the use of weight loss medication in adolescents but issued new guidelines in 2023, which recommend considering the use of weight loss medication in some overweight children aged 12 or older. The European Medicines Agency has approved semaglutide for children aged 12 or older who have a BMI in the 95 percentile for their age and a weight of at least 60 kilograms (130 lb). However, GLP-1 agonists may not be cost effective in this population.
Prior to development of AS9100 standards for Quality Management Systems, the U.S. military applied two specifications to supplier quality and inspection programs, respectively, MIL-Q-9858A Quality Program Requirements, and MIL-I-45208A Military Specification: Inspection System Requirements. For years these specifications had represented the basic tenets of the aerospace industry. However, when the U.S. government adopted ISO 9001, it withdrew those two quality standards. Large aerospace companies then began requiring their suppliers to develop quality programs based on ISO 9001. As technologies evolve, and industries become more specialized, it is likely that more updates will be made to these standards and additional specialty Quality Management Systems (QMS) requirements for various industries.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.